CONCENTRATION - Integer |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
||||||||||||||||||||||||||||||||||||||||||||||
| Concentration Risk [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
| CONCENTRATION | 15. CONCENTRATION
Vycor Medical sells its neurosurgical devices in the US primarily direct to hospitals, and internationally through distributors who in turn sell to hospitals. For the years ended December 31, 2025 and 2024, there was no customer that represented over 10% of total revenue.
Accounts Receivable Concentration
The Company has three sub-contract manufacturers from which it purchases, respectively, VBAS injection molded parts, completed and sterilized VBAS units, and extension arms. Purchases from these manufacturers vary from quarter to quarter, with no purchases in some quarters, however on an annual basis purchases from each manufacturer represent over 10% of total annual purchases.
|
||||||||||||||||||||||||||||||||||||||||||||||
| Accounts Receivable [Member] | Customer Concentration Risk [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
| Concentration Risk [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
| Number of customers over 10% | 1 | 1 | |||||||||||||||||||||||||||||||||||||||||||||
| Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
| Concentration Risk [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
| Percentage of accounts receivable | 12.00% | 11.00% | |||||||||||||||||||||||||||||||||||||||||||||